Feed ZYME
ZY

Zymeworks Inc.

ZYME · NASDAQ

$26.81 -1.18% (-$0.32)
1M -6.18%
Market Cap $1.97B
P/E Ratio -
Div. Yield -
ROE 0.74%
Piotroski F-Score Weak
2/9
Valuation
50 /100
Fair
P/B 0.02x
P/S 53.13x
P/FFO N/A
Growth
0 /100
Declining
Book val. growth 18.33%
Rev. growth 36.43%
FCF growth N/A
Profitability
20 /100
Weak
Op. margin 418.99%
Gross margin 87.78%
FCF margin 323.32%
Quality
1 /100
Poor
ROA 0.04%
ROIC 0.04%
Asset turnover 0.00x
Debt
69 /100
Low
Int. coverage -72.28x
Debt/Equity 0.20x
Current ratio 6.32x
Stability
17 /100
Unstable
EPS volatility 122.08%
Beta 1.19x
Profitable years 0

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Ask StockBot about ZYME
Online

About the company

Zymeworks Inc. (ZYME) is a Canadian biotechnology company specializing in the development of biologic drugs and therapies for oncological diseases and other serious conditions. With activities in biotechnology and pharmacology, Zymeworks Inc. is a key player in the world of innovative treatment approaches for various diseases. Their research focuses on discovering new biologic therapies and drugs that target specific biological mechanisms and pathways within the body. The company aims to provide modern and targeted treatment solutions that can bring new hope to patients with oncological and other serious diseases. Zymeworks Inc. is characterized by a high level of expertise in biotechnology and medicine. Zymeworks Inc. (ZYME) shares could be suitable for investors looking for an investment opportunity in the biotechnology sector with a company that specializes in innovative biologic treatment approaches and therapies for various serious conditions.

Sector

Healthcare

Industry

Biotechnology

CEO

Kenneth H. Galbraith

Employees

231

Headquarters

Middletown

Upcoming events

05 NOV

Earnings

Upcoming earnings report

41d

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.